On September 20, 2024, T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens, announced the successful defense of a key patent for its direct-from-whole blood detection method in the European Union. The patent, which is central to T2 Biosystems' intellectual property portfolio, faced opposition from bioMerieux and other undisclosed firms, filed with the European Patent Office (EPO) in May 2023. The EPO's Opposition Division held a public hearing on September 19, 2024, and ruled in favor of maintaining T2 Biosystems' patent, reinforcing the company's strong intellectual property position. The patent in question, European Patent No. 3 443 124, pertains to a method for amplifying a target nucleic acid characteristic of a pathogen in a whole blood sample. This victory is significant for T2 Biosystems as it continues to advance its technology, commercial platform, and product pipeline.

On September 20, 2024, T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens, announced the successful defense of a key patent for its direct-from-whole blood detection method in the European Union. The patent, which is central to T2 Biosystems' intellectual property portfolio, faced opposition from bioMerieux and other undisclosed firms, filed with the European Patent Office (EPO) in May 2023. The EPO's Opposition Division held a public hearing on September 19, 2024, and ruled in favor of maintaining T2 Biosystems' patent, reinforcing the company's strong intellectual property position. The patent in question, European Patent No. 3 443 124, pertains to a method for amplifying a target nucleic acid characteristic of a pathogen in a whole blood sample. This victory is significant for T2 Biosystems as it continues to advance its technology, commercial platform, and product pipeline.